Latest DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Stock Portfolio

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Performance:

2025 Q3: 10.19%YTD: 7.93%2024: 5.68%

Performance for 2025 Q3 is 10.19%, and YTD is 7.93%, and 2024 is 5.68%.

About DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) and 13F Hedge Fund Stock Holdings

DEERFIELD MANAGEMENT COMPANY, L.P. is a hedge fund based in NEW YORK, NY. On 31-May-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $15.1 Billions. In it's latest 13F Holdings report, DEERFIELD MANAGEMENT COMPANY, L.P. reported an equity portfolio of $6.6 Billions as of 30 Sep, 2025.

The top stock holdings of DEERFIELD MANAGEMENT COMPANY, L.P. are NUVL, CNC, MRUS. The fund has invested 23.8% of it's portfolio in NUVALENT INC and 4.9% of portfolio in CENTENE CORP DEL.

The fund managers got completely rid off OSCAR HEALTH INC (OSCR), LIQUIDIA CORPORATION (LQDA) and MEREO BIOPHARMA GROUP PLC (MREO) stocks. They significantly reduced their stock positions in BAXTER INTL INC (BAX), ALIGNMENT HEALTHCARE INC (ALHC) and EDGEWISE THERAPEUTICS INC (EWTX). DEERFIELD MANAGEMENT COMPANY, L.P. opened new stock positions in IONIS PHARMACEUTICALS INC (IONS), BRISTOL-MYERS SQUIBB CO (BMY) and BRIDGEBIO ONCOLOGY THERAPEUT. The fund showed a lot of confidence in some stocks as they added substantially to DANAHER CORPORATION (DHR), RADNET INC (RDNT) and 10X GENOMICS INC (TXG).

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Annual Return Estimates Vs S&P 500

Our best estimate is that DEERFIELD MANAGEMENT COMPANY, L.P. made a return of 10.19% in the last quarter. In trailing 12 months, it's portfolio return was -7.24%.

New Buys

Ticker	$ Bought
ionis pharmaceuticals inc	129,510,000
bristol-myers squibb co	105,433,000
ionis pharmaceuticals inc	82,657,900
neogenomics inc	62,922,600
bridgebio oncology therapeut	56,573,500
cormedix inc	38,656,200
celcuity inc	36,236,400
arrowhead pharmaceuticals in	34,248,600

New stocks bought by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Additions

Ticker	% Inc.
danaher corporation	3,722
radnet inc	2,550
10x genomics inc	2,211
haemonetics corp mass	1,857
align technology inc	1,585
corvel corp	1,416
orthopediatrics corp	1,153
ufp technologies inc	1,130

Additions to existing portfolio by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Reductions

Ticker	% Reduced
baxter intl inc	-97.78
alignment healthcare inc	-69.95
edgewise therapeutics inc	-62.96
alnylam pharmaceuticals inc	-53.15
ideaya biosciences inc	-45.01
sotera health co	-43.89
community health sys inc new	-41.26
indivior plc	-33.88

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) reduced stake in above stock

Sold off

Ticker	$ Sold
integra lifesciences hldgs c	-172,860,000
alnylam pharmaceuticals inc	-143,172,000
oscar health inc	-249,767,000
xeris biopharma holdings inc	-17,732,100
mereo biopharma group plc	-18,185,300
pulmonx corp	-4,895,100
hillevax inc	-3,746,480
liquidia corporation	-20,145,100

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) got rid off the above stocks

Sector Distribution

DEERFIELD MANAGEMENT COMPANY, L.P. has about 88.7% of it's holdings in Healthcare sector.

Sector	%
Healthcare	88.7
Others	9.5
	1.2

Market Cap. Distribution

DEERFIELD MANAGEMENT COMPANY, L.P. has about 22.1% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	46.5
LARGE-CAP	20.7
SMALL-CAP	18.3
UNALLOCATED	11.5
MEGA-CAP	1.4

Stocks belong to which Index?

About 67.8% of the stocks held by DEERFIELD MANAGEMENT COMPANY, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	51.9
Others	32.3
S&P 500	15.9

Top 5 Winners (%)		%
TOI	the oncology institute inc	133.9 %
NAMS	newamsterdam pharma company	113.9 %
ALEC	alector inc	111.4 %
MRUS	merus n v	79.0 %
TOI	the oncology institute inc	70.2 %

Top 5 Winners ($)		$
NUVL	nuvalent inc	183.1 M
MRUS	merus n v	140.6 M
UTHR	united therapeutics corp del	71.3 M
NAMS	newamsterdam pharma company	52.8 M
RVMD	revolution medicines inc	33.5 M

Top 5 Losers (%)		%
QSI	quantum si inc	-58.5 %
SBTX	ars pharmaceuticals inc	-35.0 %
NUVB	nuvation bio inc	-25.1 %
BAX	baxter intl inc	-24.8 %
BFLY	butterfly network inc	-24.4 %

Top 5 Losers ($)		$
SBTX	ars pharmaceuticals inc	-59.4 M
CNC	centene corp del	-59.2 M
BAX	baxter intl inc	-14.4 M
EHAB	enhabit inc	-7.8 M
INSP	inspire med sys inc	-7.8 M

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD MANAGEMENT COMPANY, L.P. has 144 stocks in it's portfolio. About 51.1% of the portfolio is in top 10 stocks. SBTX proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for DEERFIELD MANAGEMENT COMPANY, L.P. last quarter.

Last Reported on: 14 Nov, 2025

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACHC	acadia healthcare company in	0.45	1,189,000	29,439,600	new

ADPT	adaptive biotechnologies cor	0.01	60,328	902,507	new

AGLE	spyre therapeutics inc	0.16	613,665	10,285,000	unchanged	0.00

AHCO	adapthealth corp	1.57	11,477,700	102,726,000	added	15.88

ALEC	alector inc	0.05	1,055,190	3,123,370	unchanged	0.00

ALGN	align technology inc	0.06	32,789	4,105,840	added	1,585

ALHC	alignment healthcare inc	0.03	102,942	1,796,340	reduced	-69.95

ALNY	alnylam pharmaceuticals inc	0.47	67,935	30,978,400	reduced	-53.15

ALNY	alnylam pharmaceuticals inc	0.00	0.00	0.00	sold off	-100

AMED	amedisys inc	0.00	0.00	0.00	sold off	-100

AMPH	amphastar pharmaceuticals in	0.00	0.00	0.00	sold off	-100

ANNX	annexon inc	0.03	583,913	1,780,940	unchanged	0.00

ARWR	arrowhead pharmaceuticals in	0.52	993,000	34,248,600	new

ATEC	alphatec hldgs inc	0.01	65,262	948,909	added	282

ATRC	atricure inc	0.05	87,569	3,086,810	added	686

AVNS	avanos med inc	0.02	122,899	1,420,710	new

AVTE	jade biosciences inc	0.07	531,163	4,583,940	unchanged	0.00

AZTA	azenta inc	0.02	41,004	1,177,640	new

AZYO	elutia inc	0.02	1,371,600	1,221,000	new

BAX	baxter intl inc	0.01	42,744	973,281	reduced	-97.78